7G). These morphometric data suggest that the increase of NG2 glial cell number and their attachment to DArgic neurons may underlie the neuroprotective effects of the cytokine mixture. mRNA encoding proliferating cell nuclear antigen (PCNA, a marker

for proliferating cells) was markedly increased in the cytokine group, which may be indicative of increased NG2 glial cell numbers rather than microglia. Figure 7 Based on the processed micrographs as shown in Figure 6, the morphometrical data from Inhibitors,research,lifescience,medical the sham group (n = 5) or saline (n = 6) and cytokine groups (n = 6) were statistically analyzed and expressed as means ± SEM. PCNA-mRNA level are also shown. … Astrocytes and astrocyte-related factors in the SNpc Double-immunohistochemical staining Inhibitors,research,lifescience,medical using antibodies to GFAP and

TH was done to evaluate astrocytes in the SNpc (Fig. 8). In the SNpc of the sham rats, GFAP immunoreactivity was scarcely distributed (Fig. 8A). In contrast, GFAP immunoreactivity was increased in the saline-injected rats (Fig. 8B). However, GFAP immunoreactivity was noticeably reduced in cytokine-injected rats (Fig. 8C). In agreement with these morphologic observations, GFAP-mRNA was also increased only in the saline group. mRNAs encoding BDNF, Cu/Zn SOD, and metallothionein 2, which could most likely be from astrocytes, were increased Inhibitors,research,lifescience,medical only in the saline group. Figure 8 Reaction of astrocytes in the SNpc. (A) GFAP-immunoreactivity was weak in the SNpc Inhibitors,research,lifescience,medical (denoted with an asterisk) of sham-treated rats. (B) Strong GFAP-immunoreactivity was observed in saline-injected rats. (C) Moderate GFAP-immunoreactivity was observed … Discussion This study demonstrated that subcutaneous administration of a cytokine mixture of GM-CSF and IL-3 exhibited marked neuroprotective effects against 6-OHDA-induced Parkinsonism in rats. It is of clinical relevance that the cytokine administration was started one day after the 6-OHDA-treatment. The dose of the cytokines was 10 μg/kg bodyweight, which is comparable to Inhibitors,research,lifescience,medical the dose of

GM-CSF or IL-3 typically used for human cases to stimulate the bone marrow (Hocker et al. 1993; Bastion et al. 1995). Based on these facts, the cytokine mixture used in the present study may be clinically applicable for the treatment of PD. Furthermore, given the marked effects of this cytokine mixture in a model of PD, it can also be employed Cilengitide as a pharmacological tool to determine therapeutic scientific assay targets to prevent PD-associated neuronal death. Previously, it was shown that GM-CSF upregulates the expression of antiapoptotic factors belonging to the Bcl family in neurons selleck compound expressing GM-CSFR (Huang et al. 2007; Schabitz et al. 2008), which resulted in the prevention of neuronal cell death. IL-3 was also shown to suppress neurodegeneration through increased Bcl-xL expression (Wen et al. 1998). In this study, subcutaneous injection of the cytokine mixture induced DArgic neurons in 6-OHDA-lesioned brains to upregulate Bcl-xL expression.